Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. [artículo]
Por: Cerezo Olmos, César [Nefrología]
| García Donaire, José Antonio [Nefrología] | Ruilope Urioste, Luis Miguel [Nefrología] | Segura de la Morena, Julián [Nefrología].
Colaborador(es): Servicio de Nefrología.
Editor: Journal of Hypertension, 2012Descripción: 30(1):204-9.Recursos en línea: Solicitar documento Resumen: OBJECTIVES: Microalbuminuria has been shown to be a potent predictor for future development of cardiovascular and renal events that can be prevented by the use of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs). Both classes of drugs are now-a-days widely used in the treatment of arterial hypertension since the very early stages of the cardiorenal continuum when only cardiovascular risk factors are detected. We describe here the development of de-novo microalbuminuria in patients chronically treated with either an ACEi or an ARB at adequate doses.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC7912 (Navegar estantería) | Disponible |
Formato Vancouver:
Cerezo C, Ruilope LM, Segura J, García-Donaire JA, de la Cruz JJ, Banegas JR, et al. Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. J Hypertens. 2012 Jan;30(1):204-9.
PMID: 22080225
Contiene 30 referencias
OBJECTIVES: Microalbuminuria has been shown to be a potent predictor for future development of cardiovascular and renal events that can be prevented by the use of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs). Both classes of drugs are now-a-days widely used in the treatment of arterial hypertension since the very early stages of the cardiorenal continuum when only cardiovascular risk factors are detected. We describe here the development of de-novo microalbuminuria in patients chronically treated with either an ACEi or an ARB at adequate doses.
No hay comentarios para este ejemplar.